Quintiles to Provide Central Lab Services in Japan

Agreement with Medca Japan extends network of CAP-certified laboratories

RESEARCH TRIANGLE PARK, N.C., March 26 /PRNewswire/ -- Quintiles
Transnational Corp. today announced an agreement with Medca Japan to provide
central laboratory services, further extending the Quintiles global network of
laboratories certified by the College of American Pathologists (CAP).
Quintiles will have its own staff at the CAP-certified Medca Japan
laboratory in Saitama, a city in the Greater Tokyo area. The lab will support
clinical trials in Japan.
"Recent changes in legislation are allowing Japanese pharmaceutical
companies to extend clinical trials normally conducted in Japan to other
countries in Asia, but these companies have had difficulty finding central lab
services that are harmonized throughout the region," said Tom Wollman, Senior
Vice President, Quintiles Global Central Laboratories. "With CAP-certified
labs in Beijing, Singapore, Mumbai and now Japan, we can provide well-
controlled processes and harmonized testing services throughout the Asia-
Pacific region to customers in Japan as well as our multinational customers.
This lab, along with all labs in our network, will follow the same standard
operating procedures, and data will be available on our QNET database."
"We have established excellent systems for providing high-quality central
laboratory services based on Quintiles' global standard," said Yoh Narimatsu,
President, Quintiles Transnational Japan K.K., a subsidiary of Quintiles
Transnational. "We are determined to continue to increase clinical trials in
Japan and provide superior services for our customers through this strategic
business alliance."
Yutaka Kannari, president of Medca Japan Laboratory Co., Ltd., said he was
pleased that Medca has the capability and the high quality standards necessary
to play an important role in the expansion of Quintiles' business in Asia, and
he also sees the alliance helping Medca.
"This collaboration with Quintiles will be very helpful for the future
success of Medca Japan," he said. "We receive more than 30,000 specimens for
examination per day, and this relationship will allow us to strengthen out
clinical trial services while supporting continued growth of our existing
laboratory operations."
Medca provides a broad range of laboratory services, including biochemical
tests as well as endocrine testing, tumor marker testing, drug-level testing,
immunology testing and microbiological testing. The laboratory has undertaken
specimens for examination from about 4,000 medical institutions throughout
Japan.
The relationship with Medca will be managed within Quintiles by Alan Ong,
Vice President and General Manager, Quintiles Labs Asia, who will give
technical guidance, and Narimatsu, who will provide his expertise on the Japan
market.
CAP certification follows a site inspection. The accreditation is
intended to improve patient safety by advancing the quality of pathology and
laboratory services through education, setting standards and ensuring
laboratories meet or exceed regulatory requirements.
About Quintiles Laboratories
Quintiles Laboratories owns a CAP-certified network of clinically
harmonized facilities in the U.S., Europe, South Africa, India, China and
Singapore, and has a tightly controlled network of sub-contractor laboratories
in Argentina, Brazil and Japan managed by Quintiles employees located in each
of the sub-contractor facilities.
About Quintiles Transnational Japan K.K.
Quintiles Transnational Japan K.K. is the Japanese subsidiary of Quintiles
Transnational Corp. It is the largest contract pharmaceutical organization
(CPO) in Japan to provide total solutions such as strategic marketing services
and consultation. Quintiles Japan offers services from the Clinical
Development Division, the commercialization division Innovex and NovaQuest,
Quintiles' strategic investment and partnering group. For further information,
please visit the company's website at www.quintiles.co.jp.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
pharmaceutical, biotechnology and healthcare industries. With more than 19,000
employees and offices in more than 50 countries, it is focused on providing
customer-centric solutions that are the gold standard of the industry. For
more information, please visit the company's Web site at www.quintiles.com.
SOURCE Quintiles Transnational Corp.

Dick Jones, Media Relations, media.info@quintiles.com, +1-919-998-2091, or
Greg Connors, Investor Relations, invest@quintiles.com, +1-919-998-2000